LLS research investment has played a critical role in advancing therapies for blood cancer patients, including targeted and immunotherapies.
As there are no means of preventing or early screening for most blood cancers, the LLS research agenda is focused on finding cures. LLS drives research in areas of unmet medical need and helps to bridge the gap between academic discovery and drug development.
We fund research grants to support every discipline in the blood cancers, and we partner directly with biotechnology companies to accelerate therapies.
LLS commitment to new multi-year research grants in FY 2018.
Total LLS research investment since our inception.
"Through our commitment to basic and translational research and the new generation of scientists, and our role as a catalyst for collaboration among biotechnology, government and clinical institutions, LLS is doing more than any cancer nonprofit to advance cutting-edge research and cures."
CDP: Career Development Program
Designed to support promising investigators in their developing careers.
SCOR: Specialized Center of Research
Funds multi-institutional, multi-disciplinary teams of researchers designed to synergistically engage in collaborative efforts to discover new approaches to treat patients with blood cancers.
TRP: Translational Research Program
Designed to bring promising preclinical research findings from the laboratory to clinical development.
TAP: Therapy Acceleration Program
Strategic initiative through which we partner directly with biotechnology companies to help accelerate the development of promising therapies.
Screen To Lead/Quest For Cures
Funds innovative approaches to bolster drug discovery and address significant unmet medical needs, with the ultimate goal of advancing scientific and medical understanding of blood cancers.
Special collaborations with foundations and researchers to accelerate research, stimulate innovation and solve disease-specific challenges.
Hear from some of the world's most renowned blood cancer researchers about how LLS support helps makes it happen.
Louis J. DeGennaro, Ph.D, LLS’s president and CEO, and Steven T. Rosen, M.D., provost and chief scientific officer of City of Hope, and chairman of LLS’s Medical and Scientific Advisory Board, discuss LLS’s research funding programs.
Search the many research projects that LLS is currently funding.
LLS has invested more than $1 billion in research since our inception. Over that time, survival rates for many blood cancer patients have doubled, tripled and even quadrupled. Moreover, we have learned how to cure certain blood cancers. And many therapies first approved for blood cancers are now helping patients with other types of cancers and serious diseases.
But more than one third of blood cancer patients still do not survive five years after their diagnosis. So more funding is needed to advance more research and to ensure access to treatments to help save more lives.